161 related articles for article (PubMed ID: 33890816)
1. Immunohistochemical Detection of Cancer-Testis Antigen PRAME.
Lezcano C; Müller AM; Frosina D; Hernandez E; Geronimo JA; Busam KJ; Jungbluth AA
Int J Surg Pathol; 2021 Dec; 29(8):826-835. PubMed ID: 33890816
[TBL] [Abstract][Full Text] [Related]
2. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
[TBL] [Abstract][Full Text] [Related]
3. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.
Hemminger JA; Toland AE; Scharschmidt TJ; Mayerson JL; Guttridge DC; Iwenofu OH
Mod Pathol; 2014 Sep; 27(9):1238-45. PubMed ID: 24457462
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry for PRAME in Dermatopathology.
Lezcano C; Jungbluth AA; Busam KJ
Am J Dermatopathol; 2023 Nov; 45(11):733-747. PubMed ID: 37856737
[TBL] [Abstract][Full Text] [Related]
5. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors.
Šafanda A; Kendall Bártů M; Michálková R; Stružinská I; Drozenová J; Fabián P; Hausnerová J; Laco J; Matěj R; Škapa P; Švajdler M; Špůrková Z; Méhes G; Dundr P; Němejcová K
Virchows Arch; 2023 Oct; 483(4):509-516. PubMed ID: 37610627
[TBL] [Abstract][Full Text] [Related]
7. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
8. The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas.
Nettersheim D; Arndt I; Sharma R; Riesenberg S; Jostes S; Schneider S; Hölzel M; Kristiansen G; Schorle H
Br J Cancer; 2016 Aug; 115(4):454-64. PubMed ID: 27441500
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.
Thongprasert S; Yang PC; Lee JS; Soo R; Gruselle O; Myo A; Louahed J; Lehmann FF; Brichard VG; Coche T
Lung Cancer; 2016 Nov; 101():137-144. PubMed ID: 27794402
[TBL] [Abstract][Full Text] [Related]
11. Epitope Analysis of Murine and Chimeric Monoclonal Antibodies Recognizing the Cancer Testis Antigen PRAME.
Misyurin VA; Finashutina YP; Turba AA; Larina MV; Solopova ON; Lyzhko NA; Kesaeva LA; Kasatkina NN; Aliev TK; Misyurin AV; Kirpichnikov MP
Dokl Biochem Biophys; 2020 May; 492(1):135-138. PubMed ID: 32632590
[TBL] [Abstract][Full Text] [Related]
12. CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues.
Jungbluth AA; Chen YT; Busam KJ; Coplan K; Kolb D; Iversen K; Williamson B; Van Landeghem FK; Stockert E; Old LJ
Int J Cancer; 2002 Jun; 99(6):839-45. PubMed ID: 12115486
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis.
Ricci C; Franceschini T; Giunchi F; Grillini M; Ambrosi F; Massari F; Mollica V; Colecchia M; Fiorentino M
Am J Clin Pathol; 2022 May; 157(5):644-648. PubMed ID: 34864837
[TBL] [Abstract][Full Text] [Related]
14. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
15. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
Lezcano C; Jungbluth AA; Busam KJ
Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
[TBL] [Abstract][Full Text] [Related]
16. Application of mesothelin immunostaining in tumor diagnosis.
Ordóñez NG
Am J Surg Pathol; 2003 Nov; 27(11):1418-28. PubMed ID: 14576474
[TBL] [Abstract][Full Text] [Related]
17. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.
Iura K; Kohashi K; Hotokebuchi Y; Ishii T; Maekawa A; Yamada Y; Yamamoto H; Iwamoto Y; Oda Y
J Pathol Clin Res; 2015 Jul; 1(3):144-59. PubMed ID: 27499900
[TBL] [Abstract][Full Text] [Related]
18. PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis.
Hrycaj SM; Szczepanski JM; Zhao L; Siddiqui J; Thomas DG; Lucas DR; Patel RM; Harms PW; Bresler SC; Chan MP
Histopathology; 2022 Dec; 81(6):818-825. PubMed ID: 36102613
[TBL] [Abstract][Full Text] [Related]
19. Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential.
Naik A; Thomas R; Al-Khadairi G; Bacha R; Hendrickx W; Decock J
J Cell Mol Med; 2021 Nov; 25(22):10376-10388. PubMed ID: 34612587
[TBL] [Abstract][Full Text] [Related]
20. Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.
Hermes N; Kewitz S; Staege MS
Curr Cancer Drug Targets; 2016; 16(5):400-14. PubMed ID: 26694250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
